A major focus of the recently updated guidelines of the International Society for
Extracellular Vesicles (ISEV) on minimal information for studies of extracellular
vesicles (MISEV) is the need for appropriate (that is, informative and effective)
nomenclature in reporting extracellular vesicle (EV) research [1]. The ISEV consensus
recommendation on nomenclature is to use “extracellular vesicle” as the “generic term
for particles naturally released from the cell that are delimited by a lipid bilayer
and cannot replicate” and to modify “EV” based on clear, measurable characteristics
such as cell of origin, molecular markers, size, density, function, etc. [1]. Much
like the biological entity it describes, the term “EV” is a scaffold on which to place
further defining characteristics. MISEV does not prohibit other terms but rather specifies
that they be defined carefully at first use in a manuscript. Three hundred and eighty-two
authors contributed to the MISEV guidelines through extensive surveys, and 94% endorsed
the nomenclature recommendation. The other 6% were evenly split between disagreeing
with the recommendation (i.e. the recommendation should be stricter, less strict,
or use terms other than EV) and preferring no nomenclature recommendation.
As the corresponding authors of the latest iteration of MISEV, we recognize that although
disagreement with the MISEV recommendation was voiced by only a very small minority
of MISEV authors, the MISEV contributors represent a core of highly active EV researchers
who tend to be very collaborative and work across national and regional boundaries.
Not all EV researchers engage with initiatives like MISEV or indeed with ISEV at all.
It is possible that other groups of researchers would have a different distribution
of opinion on various MISEV topics including nomenclature. After publication of the
latest iteration of MISEV, we have received mostly positive remarks, but also some
criticism of the guidelines from a few scientists who are not authors. The criticism
we have received is overwhelmingly centred on one of two points. The first is the
issue of characterization markers (such as specific proteins) that should be depleted
in a pure EV preparation compared with the cell of origin. Here, the suggestion of
our correspondents is that MISEV is too strict, since some proposed “negative” markers
like GM130 or calnexin can be associated with some EVs and may be detectable in an
EV preparation. This criticism is easily addressed, since it is based on a misreading
or misunderstanding. In fact, MISEV2018 relaxed the recommendations of MISEV2014 [2]
in this regard, such that, while authors should give careful thought to depletion
of contaminants, there is no recommendation for a universal negative marker. That
is, for any given EV source, markers should be chosen to reveal the level of contaminants
that might be expected in that specific material. One size does not fit all!
The second major criticism is the topic of this editorial: nomenclature. Several scientists
we have corresponded with very much prefer the term “exosome” as a generic alternative
to “extracellular vesicle.” And, yes, the nomenclature disagreement is almost always
about exosomes, not microvesicles, ectosomes, microparticles, or other terms. In some
cases, we perceive an almost emotional attachment to the term exosome, as in the example
of one person who told us several times that they could not support MISEV as a matter
of “conscience.” While we cannot argue about feelings or understand why they should
enter into scientific discourse, we would like to address some other reasons that
are put forward to support the use of exosome or EV: chiefly, these are arguments
about primacy, precision, and popularity.
Primacy: the state of being first or most important
Was “exosome” first used to describe EVs?
No. “Exosome” is first found in the biomedical literature in four articles that were
published in PNAS from 1970 to 1973 [3–5]. The term described transforming DNA fragments
that transferred between Drosophila or Neurospora cells. In Neurospora, for example,
“exosomes” could induce inositol independence in inositol-requiring Neurospora mutants
[6]. These DNA exosomes were thought not to be integrated into the genome and to be
eliminated during meiosis. Although the presumed function might remind us of EVs that
carry nucleic acids, association of the DNA with lipid bilayers was not described
in these publications, so they cannot easily be construed as early descriptions of
extracellular vesicles. However, by a strict application of temporal primacy (and
we would disagree with such an application), mobile DNA fragments should be the only
use for “exosome” today.
Was “exosome” or “extracellular vesicle” first used to describe EVs?
To our knowledge, the first use of “extracellular vesicle” in the title of a scientific
publication was in 1971 in the Journal of Ultrastructure Research, “Ultrastructure
of intracellular and extracellular vesicles, membranes, and myelin figures produced
by Ochromonas danica.” This paper showed electron microscopy evidence for EV biogenesis
from O. danica, a flagellated alga [7]. Importantly, Aaronson, et al., clearly recognized
EV biogenesis as a biological phenomenon. EVs were not simply a glutaraldehyde fixation
artefact: they could be observed without glutaraldehyde fixation, and intact vesicles
could be recovered by ultracentrifugation [7]. One can also glean from this paper
that the EV was not an entirely new concept in the microscopy community in 1971. Today,
EV researchers often cite the coagulation and platelet studies of Chargaff and West
[8] and Wolff [9], or the bone matrix vesicle studies of Anderson and Bonucci [10–12]
as early evidence for the existence of EVs. In 1971, Aaronson, et al., referred to
several more studies, going back to 1960, remarking that, “(m)embranous structures
are also secreted extracellularly by mammalian cells (referring to [13]) and [by non-mammalian]
phagocytic cells (referring to [14,15]).” Additional publications in the 1970s referred
to extracellular vesicles that were observed in vitro and in vivo. To give a few example,
these include findings of EVs released from bat thyroid follicular cells during arousal
from hibernation (presaging involvement of EVs in endocrine processes) [16]; EVs in
cartilage [17,18]; and what are described as EVs released by various non-mammalian
organisms such as Candida [19], Corynebacterium [20], and Acinetobacter [21].
To be sure, EVs were referred to by several names around this time by groups working
in different fields, and it was often unclear exactly what these particles were. The
multivesicular body was first described in the 1950s [22]. Small, apparent EVs consistent
with the size of MVB particles but also with particles released from the cell surface
[23] were observed in various animal sera [24,25] and in tissue and milk of breast
cancer patients [26], and were called by names from “pequenas particulas” (little
particles) to “extracellular microvesicles” to “virus-like particles.” By the mid-1970s
at the latest, interest thus emerged in the possible relationship of several observations:
MVB intraluminal particles, microvesicles budding from the cell surface, and enveloped
viruses [27]. Van Blitterswijk et al. elaborated in a 1979 paper about EVs of ascites
fluid in murine leukaemia: “An analogy between this shedding of vesicles, the formation
of endocytotic vesicles and the budding of viruses is noted; all these processes select
or assemble rigid lipid domains of the cell membrane” [28].
The term “exosome” was not used to refer to EVs until 1981 when Trams et al. reported
on “Exfoliation of membrane ecto-enzymes in the form of micro-vesicles” [29]. The
term “micro-vesicle”/”microvesicle” was used in the title and text, but the authors
also proposed, as the last word of the abstract and discussion, that microvesicles
could be referred to as “exosomes.” Although the Trams, et al. publication was cited
on average several times per year during the 1980s, including by numerous studies
that involved extracellular vesicles, the term “exosome” was not used again in this
manner until 1986 [30], and again in 1987 by Rose Johnstone and colleagues [31]. From
the latter publication on, consensus quickly developed around the use of exosome to
describe MVB-origin EVs. We question the notion that the first-used term must necessarily
predominate. Nevertheless, the suggestion of Trams, et al. in 1981 does not establish
“primacy” for the term “exosome” as a generic term for all EVs.
Is “exosome” the most important term (i.e. if primacy = most important)?
Answering the question of “primacy” in the sense of “most important” is difficult
and depends on the value we assign to various factors. We will thus come back to this
question in the “popularity” section, below.
Precision: exactness, accuracy
What would the terms “exosome” and “extracellular vesicle” mean to a non-specialist?
And do the terms have clear definitions for the specialist?
The word “exosome” is formed from the Greek “exo” (“outside”) and “soma” (“body”).
What this term means would not be clear to a non-specialist (e.g. a biologist who
does not study EVs) without further explanation, as exact meaning cannot be discerned
immediately from the word’s constituent parts. “Outside body” could conceivably signify
numerous entities in biology. Indeed, as we have seen, “exosome” was first used to
denote mobile DNA elements. The term has also been employed in yet another way, by
Mitchell and colleagues, to name an RNA processing body in the cell: a “soma” or particle
that includes “exo”nucleases and processes/degrades RNA [32]. This use of “exosome”
was at least as common as the EV usage for some years beginning in the late 1990s.
There have thus been at least three uses of “exosome” in recent biological science.
Even for the specialist, that is, the EV scientist, the term “exosome” has a range
of inconsistent usages. Exosome has been used canonically, most consistently, and
in many cases quite rigorously since the late 1980s to mean an EV originating from
the endosomal system of the cell [31,33–37], following a pathway initially described
by the groups of Philip Stahl and Rose Johnstone [38–40]. To us, there is nothing
ambiguous or controversial about this usage to denote a distinct biogenesis compartment,
although the field has recognized increasingly that an exosome is often difficult
to recognize as such after it has left the cell (and hence the recommendations of
MISEV) [1]. Even so, the clarity of the biogenesis-based usage of “exosome” has increasingly
been compromised in the literature in favour of various usages: as a term for small
EVs, all EVs, or even a general cell releasate, where EVs are not at all rigorously
characterized. Exosomes are often said to be EVs within a particular (often arbitrary)
size range, separated using a particular method, or bearing specific cargo, but frequently
without demonstration of this presumed exclusivity. However they are defined, exosomes
are also commonly ascribed specific functions or potency, albeit frequently without
appropriate comparison with other types of EVs or fractions of cell releasates. As
such, even the specialist does not know immediately how the term is being used in
any given context.
This potentially confusing variety is not limited to “exosome,” though. Other terms
for specific types of EVs are also burdened by other usages. “Ectosome” may refer
to outer structures of sponges [41], “microvesicle” can refer to structures inside
and outside the cell [42], as well as to synthetic particles and features of tissue
damage [43], and “microparticle” has a very wide range of uses for both biological
and synthetic particles.
In contrast, the term “extracellular vesicle” should have a very clear definition
to specialist and non-specialist alike and, as mentioned, can be used as a “scaffold”
for progressively more detailed designation. As this has been covered by the consensus
MISEV2018 [1], we will not dwell on the perceived advantages or usages of EV. We conclude
that EV is an exact and accurate term (if rather broad when used alone), while exosome,
at least as commonly used, is not.
Popularity: being liked by many; fashionableness
Is exosome or EV better “liked”?
In our view, the continuing, diffuse usages of “exosome” cannot be defended by arguments
of primacy (at least in the definition of “being first”) or precision. Rather, it
would seem that exosome is simply a popular term. We have been informed (informally!)
by some colleagues that the term “exosome” has been focus group-tested by industry
and found to be the most desirable of a certain list of terms. Although we personally
have not seen these results, and do not know what terms were compared, it would stand
to reason that industry – who may wish to sell EV-based diagnostics or therapeutics
– would want to use a word that tests well amongst potential consumers. However, even
if evidence for this preference was presented publicly (and we encourage presentation
of any available data), it is not at the moment a compelling argument for us as academic
scientists to change our discourse.
Which term is most used in the literature?
Perhaps more convincing than how the term rolls off the tongue or what consumers think
of it, the number of scientific articles that use a term could be the basis for establishing
the second definition of “primacy” that thus unites with “popularity”: importance.
Indisputably, the term exosome is the most popular/used in the recent biomedical literature.
We observed above, though, that exosome often does not refer to the canonical exosome
of MVB origin and is thus diluted by many definitions (and in papers that in many
cases do not demonstrably involve EVs). As van Deun et al. recorded in their 2017
analysis of the biomedical literature, most manuscripts on EVs do not include proper
characterization of EVs generally, much less demonstration of exosomes versus other
types of EVs [44]. This lack of rigour as the field rapidly expanded in the early
2000s formed a major part of the impetus for the International Society for Extracellular
Vesicles and its standardization initiatives.
Experts … and expert consensus
Beyond overall popularity, scientific consensus is a kind of “popularity” or “agreement”
among established experts. Can we answer the question of whether the established expert
opinion has imbued “exosome” or “extracellular vesicle” with legitimacy as the best
term for EVs in general? That is a difficult question. Without doubt, MISEV2018 represents
the consensus of by far the largest group of EV experts assembled to date as an author
team, and in this sense, “extracellular vesicle” is the expert consensus for the general
term. Of course, this undisputed fact must be balanced against the many authors who
use different definitions of “exosome” individually.
Trajectory
Analyzing trajectory is another way to assess the use of specific terms for EVs. Beginning
around 2011, a return to the term “extracellular vesicle” began, driven by needs perceived
by leading experts in the field. It is admittedly unclear if the historical use was
recognized or contributed to this change. The shift around 2011 reflected a growing
recognition of both the diversity of vesicles outside the cell, including the diversity
of organisms that release them, and the difficulty of tracing vesicles back to a particular
biogenesis pathway after release. We credit this shift in large part to an influential,
highly cited review by György, et al. (Edit Buzás’s group) in 2011 [45]. The authors
of this review noted the “large number (diversity) of mobile membrane-limited vesicles”
for which they stated explicitly in their introduction, “we suggest the term ‘extracellular
vesicles’ (EVs).” The suggestion was mirrored by growing efforts in the international
community. In the same year as the publication of the review, a meeting held in Paris,
France, the “International Workshop on Exosomes” (IWE), initiated the idea of an international
scientific society dedicated to this topic. A survey held later that year among the
IWE participants, on the name to use for such a society, resulted in a majority of
votes for a generic term encompassing all possible current (and future!) subtypes
of released, membrane-enclosed vesicles. Hence, the chosen name was International
Society for Extracellular Vesicles (ISEV). The first annual meeting of ISEV was held
in 2012, followed several months later by a scientific workshop and, in early 2013,
the first two position papers of the society, both using the term “extracellular vesicle”
in the title [46,47]. From 2011 to 2013, uses of “extracellular vesicle” in the biomedical
literature tripled year-over-year and then continued to increase at a healthy rate
each year, reflecting but somewhat outpacing the increase in EV research in general.
The rate of increase for “EV,” at least for several years, was even steeper than that
for “exosome,” both in the text and the title of publications (Figure 1). However,
by 2018, articles mentioning EVs, exosomes, or any of the leading terms settled into
a roughly 25–30% rate of increase. (For a general overview of growth in the field,
we refer the reader to Roy, et al. [48].) It remains unclear if EV, no matter how
preferred as a generic term by expert consensus of the collaborative international
EV community, will reach the overall popularity of “exosome.”
10.1080/20013078.2019.1648167-F0001
Figure 1.
Usage and rate of increase of common EV terms in PubMed-indexed articles. Top left:
number of published articles from 1990 to 2018 including each term as a text word
(singular or plural), “Ectosome” here also encompasses terms such as microvesicle
and microparticle. Searches were designed with Boolean operators in an attempt to
eliminate articles unrelated to EVs, such as those including alternative definitions
as alluded to in the text (e.g. the intracellular “exosome” complex, the sponge “ectosome”,
synthetic microparticles, and intracellular microvesicles). Nevertheless, entries
from 1990 to 2007 were curated manually to remove non-EV articles. By 2008, non-EV
usages fell to <10% of the total, and manual curation was not done for subsequent
years. Since some articles use more than one term, the total (“All”) may be less than
the sum of the individual terms. Note that false negatives and positives from the
searches are possible, so all numbers should be taken as approximate. Bottom left:
year-to-year change in usage of each term, starting with 2008 and expressed as per
cent change (0 = no change). Top right: number of articles with titles containing
“exosome” (or “exosomal”) or “extracellular vesicle”. Bottom right: year-to-year change
in article title usage.
Conclusion
The term “extracellular vesicle” or “EV” has now been agreed on by the international
community as the consensus generic term for lipid bilayer-delimited particles released
from the cell [1]. Here, we have highlighted some of the historical work on EVs that
established the primacy of this term before “exosome” was first used or reached its
current consensus definition as an EV from the endosomal system. Nevertheless, a perceived
popularity of the term “exosome” has resulted in its application as a generic descriptor
of EVs. In the end, precision and consensus terminology are ideal, but authors will
inevitably use the terms they prefer. When authors choose not to follow the consensus,
we can only recommend, in the spirit of a previous letter to the editor [49], that
terms other than EV are clearly defined at each use.